/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update regarding.
Clinical studies reveal extended survival in diffuse midline glioma patients receiving ONC201 treatment; research also explains the underlying mechanism of the drug’s success. For the first time, a potential drug candidate has been identified by researchers that show promise in improving outcomes f
Research Uncovers Survival Boost for Incurable Brain Tumor miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Researchers have partnered to create a first-of-its-kind open-source, reproducible analysis platform for pediatric brain tumors. With the help of thousands of genomically sequenced samples, researchers have used this platform to identify initial findings about genetic variants associated with poorer outcomes that could help guide future diagnostic and therapeutic advances.